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Abstract
Coronary perivascular adipose tissue (PVAT) is a naturally occurring adipose tissue depot that
normally surrounds the major coronary arteries on the surface of the heart. While originally
thought to promote vascular health and integrity, there is a growing body of evidence to support
that coronary PVAT displays a distinct phenotype relative to other adipose depots and is capable
of producing local factors with the potential to augment coronary vascular tone, inflammation, and
the initiation and progression of coronary artery disease. The purpose of the present review is
outline previous findings regarding the cardiovascular effects of coronary PVAT and the potential
mechanisms by which adipose-derived factors may influence coronary vascular function and the
progression of atherogenesis.
Introduction
Coronary perivascular adipose tissue (PVAT) is a visceral adipose tissue of mesothelial
origin that normally surrounds the major coronary arteries on the surface of the heart1, 2.
Coronary PVAT is functionally distinct from the adipose tissue found on the surface of the
myocardium, which is defined as myocardial (epicardial) adipose tissue (mEAT)3, 4. In
addition to adipocytes and pre-adipocytes, coronary PVAT contains fibroblasts,
macrophages, leukocytes, as well as blood vessels and autonomic nerves. With no fascia
separating PVAT from the coronary circulation and myocardium, these essential
components of the heart share the same microcirculation1. Originally perceived as a
relatively ubiquitous and benign tissue that largely provides structural support and
insulation5, 6, it is becoming clear that factors derived from PVAT (adipokines) are capable
of influencing a variety of key (patho)physiologic parameters. In particular, recent data
support that cardiac adiposity expands with obesity7, that atherosclerotic plaques occur
predominately in coronary arteries that are encased in PVAT7-10, and that coronary PVAT
volume is positively associated with underlying plaque burden11. Patients with high mEAT
volume have also been shown to have a higher incidence of atrial fibrillation, independent of
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left atrium enlargement12-14. As such, cardiac adiposity has been identified as an
independent risk factor for coronary artery disease8, 15, 16 and a predictor of future coronary
events17. While specific adipokines can serve to promote vascular health and
integrity5, 18, 19, evidence is mounting in support of marked up-regulation of pro-atherogenic
mRNA and protein expression profiles in coronary PVAT and mEAT in the setting of
obesity20-25. This aberrant regulation of coronary PVAT also correlates with underlying
vascular dysfunction and disease in obesity23, 26-30. Thus, there is growing evidence to
support the hypothesis that local alterations in PVAT-derived factors contribute to the
initiation, progression and expansion of coronary disease24, independent of changes in
visceral adipose tissue and/or systemic adipokine levels that may occur in the setting of
obesity31. The purpose of the present review is to outline current data regarding the
cardiovascular effects of coronary PVAT and the potential mechanisms by which adipose-
derived factors may influence coronary endothelial and smooth muscle function and the
progression of atherogenesis.
Vascular Effects of Peripheral vs. Coronary PVAT
Initial studies in to the vascular effects of peripheral (non-cardiac) PVAT demonstrated
significant reductions in contractile responses to a variety of agonists in aorta32-35,
mesenteric36-38, and human internal thoracic arteries39, 40. This “anti-contractile” (or
ADRF) vasodilator effect has been attributed to PVAT-derived adiponectin41, hydrogen
sulfide (H2S)37, hydrogen peroxide (H2O2)33, and Ang1-742 mediated vasodilation via the
opening of voltage-dependent KV7 channels37, BKCa channels40, 43 and/or Kir channels33.
In contrast, the presence of peripheral PVAT has also been shown to potentiate contraction
of mesenteric arteries to electrical field stimulation via increased production of angiotensin
II and superoxide44, 45. Recent data from Watts et al. implicate chemerin as a PVAT-derived
constricting factor in aortic and mesenteric vascular beds46. Thus, non-cardiac PVAT is
capable of producing factors that illicit both vasodilation and vasoconstriction.
Experiments to elucidate the vascular effects of coronary PVAT are rather limited and
somewhat conflicting. Studies in isolated coronary arteries from lean or
hypercholesterolemic swine show little to no effect of coronary PVAT on endothelial-
dependent vasodilation or coronary contractile responses to endothelin-1, angiotensin II, or
the thromboxane A2 mimetic U4661947-49. Alternatively, coronary PVAT has been found to
diminish endothelial-dependent dilation in dogs29, 50 and to significantly exacerbate
underlying coronary endothelial dysfunction in obese swine48. Further studies in “clean”
(PVAT free) conduit coronary arteries revealed that the addition of coronary PVAT from
lean swine augments contractile responses to KCl-induced depolarization and to
prostaglandin F2α in proportion to the amount of PVAT added to the bath23. Interestingly,
this effect was also observed in response to mesenteric PVAT, but not subcutaneous PVAT.
Furthermore, the constricting effect of coronary PVAT was markedly exaggerated in
endothelium intact and denuded coronary arteries from obese swine. Additional findings
support that these enhanced effects are associated with substantial alterations in the protein
expression of obese coronary PVAT23, 24 and with inherent differences in the phenotype of
obese smooth muscle cells51, 52. Taken together, these findings indicate that factors derived
from coronary PVAT can act to impair endothelial-dependent dilation and potentiate
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contractions of coronary vascular smooth muscle, especially in the setting of obesity.
Potential mediators and mechanisms of these influences are discussed below.
In summary, the findings to date indicate that the vascular effects of PVAT are highly
dependent upon anatomical location of the artery/adipose tissue depot, the species being
studied, the pharmacologic agonist(s) used, and the underlying phenotype of the
endothelium and smooth muscle in relation to the overall health status of the studied
model23, 53. Generally, PVAT from peripheral beds exerts vasodilator “anti-contractile”
influences whereas coronary PVAT tends to induce vasoconstrictor effects, which includes
attenuation of endothelial-dependent dilation. It is important to recognize that the
experimental evidence thus far derives from in vitro examination of isolated arteries. Thus,
the functional (physiologic) relevance of these vascular influences on the regulation of blood
pressure, organ blood flow, and/or progression of disease remains a critical and
experimentally difficult question to address moving forward. In addition, more careful
examination of the precise cell types and mediators responsible for these effects is also
warranted.
Expression Profiles in Coronary PVAT
Recent evidence supports that there are substantial differences in gene and protein
expression in different adipose tissue depots (e.g. subcutaneous vs. coronary) and that these
profiles are significantly altered in the setting of disease. Examination of PVAT surrounding
the major coronary arteries suggests that this adipose depot is phenotypically consistent with
both white and brown adipose tissue54, 55. Data from the Weintraub laboratory indicate that
adipocytes from human coronary PVAT exhibit a reduced state of adipogenic differentiation
compared to adipocytes from other depots from the same subjects (e.g. subcutaneous or
perirenal-visceral)56 and that expression of pro-inflammatory genes and secretion of
cytokines such as IL-6, IL-8, and monocyte chemoattractant protein (MCP-1) is markedly
elevated in coronary PVAT vs. other adipose tissue depots and/or in the presence of
coronary artery disease20, 56 (see Table). Furthermore, recent findings from our laboratory as
well as others support that this heightened pro-inflammatory environment of coronary
PVAT is markedly exacerbated by obesity and/or with the progression of coronary artery
disease21-23, 26, 31, 48, 57-59. In particular, increased expression of “pro-atherogenic” factors
including leptin, resistin, tumor necrosis factor-α, IL-6, chemerin and calpastatin have been
documented to date9, 23, 26, 46, 48, 57, 60-64. Diminished expression of potentially
“vasculoprotective” proteins such as adiponectin, which has been associated with
improvements in endothelial function65, has also been demonstrated in human coronary
PVAT in the setting of obesity and coronary artery disease26, 31, 58, 66, 67, 68 (see Figure).
Interestingly, augmented expression of the osteogenic factors osteoprotegerin20 and
osteoglycin23 were also recently identified in coronary PVAT. These factors have been
previously linked with atherosclerosis and the severity of coronary artery disease69, 70.
Accordingly, strong and growing evidence supports that coronary PVAT displays a distinct
phenotype relative to other adipose tissue depots and is capable of locally producing factors
with the potential to influence the initiation and progression of coronary vascular
dysfunction and disease.
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Within the context of coronary PVAT expression profiles it is important to consider how
factors produced in the coronary adventitia are able to traverse the arterial wall to influence
the endothelium and/or vascular smooth muscle. The current hypothesis is that the vasa
vasorum, a network of small vessels that supply blood to the walls of large blood vessels, is
interspersed within the PVAT and thus is capable of delivering adventitial-derived factors to
conduit coronary arteries71-73. This hypothesis is supported by prior studies which have
demonstrated that neovascularization of the coronary vasa vasorum precedes the
development of overt endothelial dysfunction in swine fed a high cholesterol diet72 and by
experiments which found increases in blood flow through the vasa vasorum to the intima of
atherosclerotic coronary arteries of monkeys74. Neovascularization originating from the
adventitia has also been associated with the extent of inflammation and coronary disease in
humans75. Although the temporal association between expansion of the coronary vasa
vasorum and the development endothelial dysfunction and atherosclerosis is intriguing,
further studies to directly examine this hypothesis for the transit of PVAT-derived factors
across the coronary wall are needed.
Pathways Influenced by Coronary PVAT
As outlined above, initial studies regarding the vascular effects of coronary PVAT have
shown that factors produced by this depot can impair endothelial-dependent vasodilation and
augment coronary smooth muscle constriction, especially in the setting of obesity23, 24. At
present we are far from understanding the precise factors and signaling pathways
responsible for the vascular effects of coronary PVAT. However, there are recent
investigations which provide insight regarding potential mechanisms of PVAT-induced
coronary vascular dysfunction.
Data from our laboratory support that coronary PVAT significantly attenuates endothelial
dependent dilation of isolated coronary arteries in the setting of obesity48. This endothelial
dysfunction was associated with elevated expression of the adipokine leptin, which we have
demonstrated induces significant reductions in coronary endothelial nitric oxide production
via a PKC-β dependent phosphorylation of eNOS at the Thr495 inhibitory site48, 50, 62. This
hypothesis is supported by additional studies that found that the endothelial effects of obese
coronary PVAT are abrogated by the inhibition of leptin receptors with a recombinant,
pegylated leptin antagonist or by the inhibition of PKC-β with ruboxistaurin48. These
findings are corroborated by data from other laboratories which have documented increased
activation of PKC-β in obesity76-79. Prior studies have also implicated leptin in other key
aspects of atherogenesis, including: 1) monocyte chemattraction80; 2) promotion of
cholesterol ester accumulation in foam cells81; 3) reduction of plasma high density
lipoprotein cholesterol and apolipoprotein A-I concentrations82, 83; 4) activation of acute
phase reactants84, 85; 5) elevation of oxidative stress and modification of plasma
lipoproteins86; 6) augmented DNA-binding activity of proinflammatory transcription
factors87.
Alternatively, reductions in adiponectin expression in obese coronary PVAT could facilitate
inflammation, endothelial dysfunction, and atherogenesis as recent data from Karastergiou
et al. indicate that administration of recombinant adiponectin successfully reversed PVAT-
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mediated increases in endothelial adhesion molecule expression (ICAM-1) and adhesion of
monocytic cells to human coronary artery endothelial cells61. PVAT-derived adiponectin
has also been shown to improve the bioavailability of nitric oxide in gluteal arteries obtained
from healthy, but not obese humans41. Prior studies also demonstrate that adiponectin
administration diminishes oxidative stress, inflammation, and improves endothelial function
via adenosine monophosphate-activated protein kinase (AMPK)-induced phosphorylation of
eNOS at Thr176 65, 88, 89. Taken together, these findings suggest that an imbalance between
pro-atherogenic vs. anti-atherogenic PVAT-derived adipokines could serve to activate a
number of key regulatory pathways to promote obesity-induced coronary artery disease at a
local level. Alterations in these pathways, along with other adipokines such as resistin and
tumor necrosis factor-α that are known to negatively impact endothelial function and
vascular remodeling90-95 should be further explored.
Recently, Owen et al. documented that coronary PVAT is capable of releasing factors that
initiate and/or potentiate coronary contraction via activation of voltage-dependent ion
channels (i.e. CaV1.2 channels)23. This effect of PVAT was substantially augmented in
tissues obtained from obese relative to lean swine, thus suggesting that obesity increases
production of “adipose-derived constricting factors” from coronary PVAT. A global
proteomic assessment of coronary PVAT supernatant from lean and obese swine revealed
substantial alterations in key regulatory pathways, including cellular growth and
proliferation (51 molecules) and cellular movement (39 molecules). Of particular interest
were increases in RhoA (2.9-fold) and calpastatin (1.6-fold) which are directly linked to
smooth muscle contraction, Ca2+ sensitization, and the progression of hypertension96, 97.
Further studies to examine the effects of calpastatin, a known endogenous calpain
inhibitor97, 98 revealed that this protein dose-dependently augments contractions of isolated
coronary arteries similarly to that of coronary PVAT. Interestingly, interrogation of the Rho-
kinase pathway revealed that coronary contractions to lean PVAT are largely mediated via a
Rho-dependent pathway, whereas enhanced coronary contractions to obese coronary PVAT
occurred independent of Rhokinase signaling (was unaffected by the inhibition of Rho-
kinase). These data, along with concurrent evidence that PVAT-derived factors significantly
impair coronary vasodilation of H2O2-sensitive K+ channels23, indicate that the effects of
coronary PVAT are related not only to inherent alterations in coronary PVAT expression
profiles but also to underlying mechanistic differences in obese coronary artery smooth
muscle cells. This hypothesis is supported by earlier studies from our laboratory and others
which have demonstrated that obesity decreases the functional expression of coronary K+
channels99-103 and increases coronary CaV1.2 channel current, expression, and
contraction51, 52, 104.
Implications and Conclusions
Taken together, there is a growing body of evidence to support that changes in the
phenotypic expression patterns in coronary PVAT occur concomitantly with mechanistic
alterations in endothelium and vascular smooth muscle. These changes appear to be
dependent on the unique characteristics of the cell types involved and the underlying
environment/milieu in which they reside. However, the extent to which PVAT-derived
factors “causally” contribute to changes in vascular expression of K+ channels, Ca2+
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channels, Rho-signaling, macrophage/foam cell formation, and/or regional heterogeneity of
smooth muscle differentiation/proliferation and atheroma progression has not been
determined. Future research to delineate the involvement of specific adipose tissue cell
types, how adipose tissue-derived factors are delivered to the vascular wall and possibly
systemic circulation (i.e. vasa vasorum), identity of precise mediators, as well as signaling
pathways and end-effector mechanisms influenced by coronary perivascular and epicardial
adipose tissue beds remain central questions moving forward.
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Significance
There is a growing body of evidence to support that changes in the phenotypic expression
patterns in coronary perivascular adipose tissue (PVAT) occur concomitantly with
mechanistic alterations in endothelium and vascular smooth muscle in the setting of
cardiovascular disease. These changes appear to be dependent on the unique
characteristics of the cell types involved and the underlying environment/milieu in which
they reside. This review summarizes current findings regarding the cardiovascular effects
of coronary PVAT and outlines potential mechanisms by which adipose-derived factors
may influence coronary disease.
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Figure 1.
Schematic diagram outlining known alterations in coronary PVAT-derived adipokines and
potential downstream effector mechanisms in endothelium and vascular smooth muscle.
Leptin released from coronary PVAT diminishes eNOS activity, preventing nitric oxide
mediated dilation of vascular smooth muscle via activation of K+ channels and contributes
to the recruitment of macrophages and retention of foam cells in the extravascular space.
Calpastatin and an unknown adipose-derived constricting factor(s) (ADCF) increase
vasoconstriction via CaV1.2 channels and may function to increase RhoA activity in healthy
coronary smooth muscle. Other adipokines implicated in other vascular beds may also play a
role in promoting coronary vascular endothelial and smooth muscle dysfunction, including,
but not limited to: increases in resistin, chemerin, osteoglycin, osteoprotegerin, and
decreases in adiponectin production.
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Table
Comparison of coronary perivascular and subcutaneous adipose tissue adipokine expression.
Adipokine Condition Coronary PVAT ExpressionRelative to Subcutaneous References
Leptin NCAD ↓ mRNA 60
CAD ↓ mRNA 57
Adiponectin NCAD ↓ mRNA, ↓ protein secretion 60
CAD ↑ protein secretion 26
TNF-α NCAD+CAD ↑ mRNA 64
CAD ↑ mRNA, ↑ protein secretion 63
↓ protein secretion 26
IL-6 NCAD ↑ mRNA 60, 20
NCAD+CAD ↑ mRNA 64
CAD ↓ mRNA 57
↑ protein secretion 63
IL-1β NCAD+CAD ↑ mRNA 64
CAD ↑ mRNA, ↑ protein secretion 63
MCP-1 NCAD ↑ protein secretion 60
NCAD+CAD ↑ mRNA 64
CAD ↑ mRNA, ↑ protein secretion 63
PAI-1 CAD ↓ mRNA 57
NCAD, no coronary artery disease; CAD, coronary artery disease; NCAD+CAD, grouped population of NCAD and CAD; TNF-α, tumor necrosis
factor-alpha; IL-6, interleukin-6; IL-1β, interleukin-1 beta; MCP-1, monocyte chemoattractant protein-1; PAI-1, plasminogen activator inhibitor-1.
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